Referred to the House Committee on Education and Workforce.
The Cancer Drug Parity Act of 2025 would add a new section to ERISA requiring group health plans and health insurance offered in connection with such plans to ensure that cost-sharing (deductibles, coinsurance, copays, and similar out-of-pocket limits) for FDA-approved, prescribed, patient‑administered oral anticancer medications is no less favorable than the cost-sharing for anticancer medications administered intravenously or by injection by a health care provider. The requirement applies only when the treating physician determines the oral medication is medically necessary or clinically appropriate.
Scope and cost trade-offs: liberals emphasize patient access and are willing to accept potential plan costs; conservatives emphasize employer/plan cost and federal mandate concerns.
Relative to its intended legislative type, this bill is a well‑targeted substantive amendment to ERISA that clearly defines the core obligation (cost‑sharing parity for oral anticancer drugs) and includes several protective and integrative provisions, plus a GAO study to evaluate impact.
The Cancer Drug Parity Act of 2025 would add a new section to ERISA requiring group health plans and health insurance offered in connection with such plans to ensure that cost-sharing (deductibles, coinsurance, copays, and similar out-of-pocket limits) for FDA-approved, prescribed, patient‑administered oral anticancer medications is no less favorable than the cost-sharing for anticancer medications administered intravenously or by injection by a health care provider.
The requirement applies only when the treating physician determines the oral medication is medically necessary or clinically appropriate.
Plans may not comply by redesigning benefits in ways that increase out-of-pocket costs or by imposing more restrictive limits on oral anticancer drugs, but the bill allows plans to continue to require prior authorization and other utilization controls.
On content alone the bill is a narrowly tailored, administrable change aimed at improving access to oral cancer drugs, which tends to attract sympathetic support. Key obstacles are the mandate on ERISA-covered plans (which can provoke insurer/employer resistance) and the Senate's higher procedural hurdles; absence of explicit federal spending reduces budgetary objections but does not eliminate stakeholder pushback.
Relative to its intended legislative type, this bill is a well‑targeted substantive amendment to ERISA that clearly defines the core obligation (cost‑sharing parity for oral anticancer drugs) and includes several protective and integrative provisions, plus a GAO study to evaluate impact. It leaves implementation details such as enforcement modalities, regulatory guidance responsibilities, fiscal impacts, and precise compliance measurement to existing ERISA structures or future action.
Scope and cost trade-offs: liberals emphasize patient access and are willing to accept potential plan costs; conservatives emphasize employer/plan cost and federal mandate concerns.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and cost trade-offs: liberals emphasize patient access and are willing to accept potential plan costs; conservatives emphasize employer/plan cost and federal mandate concerns.
A mainstream liberal would likely view this bill as a pragmatic consumer-protection measure that reduces a common disparity that creates financial barriers to oral cancer treatments.
They would emphasize the patient-access and equity aspects: ensuring oral anticancer drugs are as affordable to patients as IV/injectable treatments.
They would likely welcome the GAO study requirement to quantify impacts and push for broader scope if needed.
A moderate/centrist would generally favor the bill’s patient-access goal but want to weigh trade-offs between lowering out-of-pocket costs and potential impacts on premiums, employer costs, and plan design.
They would appreciate the targeted, time-limited scope (group plans, physician determination) and the GAO study, but would seek cost estimates and implementation details before full endorsement.
They would also look to preserve reasonable plan management tools (the bill explicitly allows prior authorization).
A mainstream conservative would be sympathetic to the intention of reducing patient costs for cancer drugs but cautious about a new federal mandate imposed on employer-sponsored plans under ERISA.
They would worry about increased costs for employers and insurers, potential premium increases for workers, and federal overreach into private plan design.
They would emphasize preserving plan flexibility to manage costs and might prefer a market-based or state-driven solution rather than an ERISA amendment.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone the bill is a narrowly tailored, administrable change aimed at improving access to oral cancer drugs, which tends to attract sympathetic support. Key obstacles are the mandate on ERISA-covered plans (which can provoke insurer/employer resistance) and the Senate's higher procedural hurdles; absence of explicit federal spending reduces budgetary objections but does not eliminate stakeholder pushback.
The bill has not accumulated any surfaced votes yet.
Scope and cost trade-offs: liberals emphasize patient access and are willing to accept potential plan costs; conservatives emphasize employ…
On content alone the bill is a narrowly tailored, administrable change aimed at improving access to oral cancer drugs, which tends to attra…
Relative to its intended legislative type, this bill is a well‑targeted substantive amendment to ERISA that clearly defines the core obligation (cost‑sharing parity for oral anticancer drugs) and includes several protec…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.